EconBiz - Find Economic Literature
    • Logout
    • Change account settings
  • A-Z
  • Beta
  • About EconBiz
  • News
  • Thesaurus (STW)
  • Academic Skills
  • Help
  •  My account 
    • Logout
    • Change account settings
  • Login
EconBiz - Find Economic Literature
Publications Events
Search options
Advanced Search history
My EconBiz
Favorites Loans Reservations Fines
    You are here:
  • Home
  • Search: subject:"Pharmacoeconomics and Health Outcomes"
Narrow search

Narrow search

Year of publication
Subject
All
Pharmacoeconomics and Health Outcomes 17 Health Economics 16 Public Health 16 Health Administration 14 Quality of Life Research 14 Health Care Management 3 Economic Policy 2 Public Finance 2 Arzneimittel 1 Arzneimittelmarkt 1 Gesundheitskosten 1 Gesundheitsversorgung 1 Gesundheitswesen 1 Gesundheitsökonomik 1 Health Care 1 Health care 1 Health care costs 1 Health care system 1 Health economics 1 Industrial chemistry & chemical engineering 1 Market Access 1 Medical & healthcare law 1 Medical Law 1 Pharma Management 1 Pharmaceutical Sciences/Technology 1 Pharmaceutical distributors 1 Pharmaceutical industry 1 Pharmaceutical market 1 Pharmaceuticals 1 Pharmaceutics 1 Pharmacology 1 Pharmacy 1 Pharmacy / dispensing 1 Pharmahandel 1 Pharmaindustrie 1 Pharmakologie 1 Quality Control 1 Quality management 1 Qualitätsmanagement 1 Regulatory Affairs 1
more ... less ...
Online availability
All
Free 17 CC license 1
Type of publication
All
Article 16 Book / Working Paper 1
Type of publication (narrower categories)
All
Article 16 Aufsatzsammlung 1
Language
All
English 17
Author
All
Stargardt, Tom 4 Albright, Ann 1 Ali, Mohammed K. 1 Baier, Natalie 1 Baumann, Mathias 1 Betsch, Cornelia 1 Böhm, Anna-Katharina 1 Büssgen, Melanie 1 Chernyak, Nadja 1 Dagres, Nikolaos 1 Del Giudice, Pietro 1 Dingermann, Theodor 1 Dintsios, Charalabos-Markos 1 Eisemann, Nora 1 Elsner, Christian 1 Frey, Simon 1 Frielitz, Fabian-Simon 1 Gandjour, Afschin 1 Gregg, Edward W. 1 Hadwiger, Moritz 1 Hapfelmeier, Alexander 1 Hapfelmeier, Jana 1 Heider, Ann-Kathrin 1 Hindricks, Gerhard 1 Jamalabadi, Sara 1 Jansen, Christian 1 Katalinic, Alexander 1 Kistler, Martin 1 Kourouklis, Dimitrios 1 Laxy, Michael 1 Mang, Harald 1 Müller, Dirk 1 Ng, Boon Peng 1 Russe, Otto 1 Sax, Lisa-Marie 1 Schneider, Antonius 1 Schneider, Udo 1 Schreyögg, Jonas 1 Schulenburg, J.-Matthias Graf von der 1 Schweizer, Lars 1
more ... less ...
Published in...
All
Applied Health Economics and Health Policy 14 The European Journal of Health Economics 2
Source
All
EconStor 16 ECONIS (ZBW) 1
Showing 1 - 10 of 17
Cover Image
Medication Adherence and Healthcare Costs in Chronically Ill Patients Using German Claims Data
Wendl, Johannes; Simon, Andreas; Kistler, Martin; … - In: Applied Health Economics and Health Policy 21 (2023) 3, pp. 477-487
Background and Objective: Despite the importance of medication adherence for chronically ill patients and the vast literature on its relationship to costs, this field suffers from methodological limitations. These are caused, amongst others, by the lack of generalizability of data sources,...
Persistent link: https://www.econbiz.de/10015191348
Saved in:
Cover Image
Authors’ Reply to Gandjour: “10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?”
Büssgen, Melanie; Stargardt, Tom - In: Applied Health Economics and Health Policy 22 (2023) 1, pp. 127-128
Persistent link: https://www.econbiz.de/10015191381
Saved in:
Cover Image
Economic Effects of Fixed-Dose Versus Loose-Dose Combination Therapy for Type 2 Diabetes Patients
Böhm, Anna-Katharina; Schneider, Udo; Stargardt, Tom - In: Applied Health Economics and Health Policy 21 (2022) 1, pp. 109-118
Objective: We examined the effects of fixe-dose combinations (FDCs) versus loose-dose combinations (LDCs) on costs from the payer and patient perspective and investigated potential channels contributing to differences in costs between the two modes of treatment. Methods We investigated...
Persistent link: https://www.econbiz.de/10015191369
Saved in:
Cover Image
How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?
Dintsios, Charalabos-Markos; Chernyak, Nadja - In: Applied Health Economics and Health Policy 20 (2021) 3, pp. 287-290
Persistent link: https://www.econbiz.de/10014497506
Saved in:
Cover Image
COVID-19: not the time for health economists? A plea for more proactive health economic involvement
Schulenburg, J.-Matthias Graf von der - In: The European Journal of Health Economics 22 (2021) 7, pp. 1001-1004
Persistent link: https://www.econbiz.de/10014497528
Saved in:
Cover Image
Financial Incentives in the Path to Recovery from the COVID-19 Pandemic
Gandjour, Afschin - In: Applied Health Economics and Health Policy 20 (2021) 1, pp. 5-8
Persistent link: https://www.econbiz.de/10014497585
Saved in:
Cover Image
Comment on: “Willingness to Pay for a COVID-19 Vaccine”
Sprengholz, Philipp; Betsch, Cornelia - In: Applied Health Economics and Health Policy 19 (2021) 4, pp. 619-621
Persistent link: https://www.econbiz.de/10014497607
Saved in:
Cover Image
Impact of Guidelines on the Diffusion of Medical Technology: A Case Study of Cardiac Resynchronization Therapy in the UK
Vadia, Rucha; Stargardt, Tom - In: Applied Health Economics and Health Policy 19 (2020) 2, pp. 243-252
Introduction Research on clinical practice guidelines as a determinant of the diffusion of medical technology remains sparse. We aim to evaluate the impact of guidelines on the awareness of medical technology, as a proxy of its use, with the example of cardiac resynchronization therapy (CRT) in...
Persistent link: https://www.econbiz.de/10014497485
Saved in:
Cover Image
Implementing Lifestyle Change Interventions to Prevent Type 2 Diabetes in US Medicaid Programs: Cost Effectiveness, and Cost, Health, and Health Equity Impact
Laxy, Michael; Zhang, Ping; Ng, Boon Peng; Shao, Hui; … - In: Applied Health Economics and Health Policy 18 (2020) 5, pp. 713-726
Background: Lifestyle change interventions (LCI) for prevention of type 2 diabetes are covered by Medicare, but rarely by US Medicaid programs that constitute the largest public payer system in the USA. We estimate the long-term health and economic implications of implementing LCIs in state...
Persistent link: https://www.econbiz.de/10014497533
Saved in:
Cover Image
Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
Shaikh, Mujaheed; Del Giudice, Pietro; Kourouklis, Dimitrios - In: Applied Health Economics and Health Policy 19 (2020) 2, pp. 217-229
Background: A trade-off exists between affordability of pharmaceutical products today and incentives for firms to provide new and better drugs in the future; an activity that prior studies suggest correlates with profitability, which in turn depends on price regulation. Objective In this paper we...
Persistent link: https://www.econbiz.de/10014497536
Saved in:
  • 1
  • 2
  • Next
  • Last
A service of the
zbw
  • Sitemap
  • Plain language
  • Accessibility
  • Contact us
  • Imprint
  • Privacy

Loading...